First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma. jkcvhl. 2025;12(2):27-36. doi:10.15586/jkcvhl.v12i2.387